Category: CareFusion Corp.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Stryker Corp.
, Valeant Pharmaceuticals
, Allergan Inc.
Becton Dickinson plans to cut the debt load from its $12 billion acquisition of CareFusion by some $1.4 billion after realizing it has more cash available that it thought.
Becton Dickinson's $12.2 billion bid for device maker CareFusion clears the required waiting period under U.S. anti-trust regulations.
Sales and earnings rise during the fiscal 1st quarter for CareFusion as it prepares to be absorbed by Becton, Dickinson & Co.
CareFusion (NYSE:CFN) ended its last fiscal quarter as a public company on a strong note, posting earnings growth of 2.8% on a top-line gain of 11.1%.
Here's a look at some of the top Wall Street stories for medical device companies this week: Wall Street loves Edwards Lifesciences again; Becton Dickinson to buy CareFusion for $12 billion in cash, stock; Proxy war rages on at Echo Therapeutics; Platinum fires back at Echo Therapeutics over 'rogue' directors; Echo Therapeutics hits back at Platinum Equity
What does news of yet another mega-merger mean for medtech's industry council?
The winds of change in medtech are blowing in the Windy City.
As medtech's best & brightest descended on Chicago for another annual confab at AdvaMed 2014, it was impossible to ignore that the industry has now entered the great age of consolidation with yet another multibillion-dollar healthcare deal.
Becton Dickinson & Co. agrees to pay $12 billion in cash and stock for CareFusion Corp.